MidEuropa Backs FAMAR’s European Expansion with Acquisition of Sterile Manufacturing Site in Germany

MidEuropa, a leading European private equity investor with deep roots in Central Europe supported the closing of the acquisition of the sterile manufacturing site in Homburg (Saar), Germany—formerly owned by MiP Pharma—by its portfolio company, FAMAR Group. This strategic milestone significantly strengthens FAMAR’s footprint in high-value dosage forms by expanding capabilities in aseptic and lyophilized fill & finish.

The Homburg facility, which has recently undergone significant investment and modernization, will become an integral part of FAMAR’s international manufacturing network. FAMAR now operates seven facilities across Europe, enhancing its ability to serve its customers with flexible, high-quality, and scalable production solutions.

Matthew Strassberg, Partner and Head of Healthcare at MidEuropa commented: “This deal highlights our conviction in FAMAR’s strategy and our capability to support international expansion of our portfolio companies. By providing substantial new equity, we are ensuring that FAMAR has the resources needed to serve its global customer base and accelerate its long-term growth.”